Overview

Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD

Status:
NOT_YET_RECRUITING

Trial end date:
2028-04-01

Target enrollment:

Participant gender:

Summary

This is an open-label, single-arm, phase 3b/4 study to assess the safety and efficacy of mirikizumab in approximately 60 participants with stricturing CD.

Phase:

PHASE4

Details

Lead Sponsor:

Alimentiv Inc.

Treatments:

mirikizumab